OPK Q4 Earnings & Revenues Beat Estimates, Gross Margin Contracts

Core Insights - OPKO Health, Inc. reported a loss per share of 4 cents in Q4 2025, an improvement from a 1 cent earnings per share in the same quarter last year, beating the Zacks Consensus Estimate of a 7 cents loss by 42.9% [1][10] Revenue Summary - OPKO Health's revenues for Q4 2025 were $148.5 million, a decrease of 19.1% year over year, but exceeded the Zacks Consensus Estimate by 7.6% [2][10] - The decline in overall revenue was attributed to lower service revenues, partially offset by increased product revenues, particularly from Rayaldee [2] Segmental Revenue Breakdown - The Diagnostics segment generated $71.7 million in service revenues, down 30.5% year over year, primarily due to reduced clinical test volumes following the sale of certain BioReference assets [4] - The Pharmaceuticals segment saw product revenues rise by 16.8% year over year to $43.7 million, driven by higher sales volumes in international markets, despite a decrease in Rayaldee sales [5] - Revenues from the transfer of intellectual property and other sources totaled $33.7 million, down 21.8% from the previous year due to lower milestone payments and reduced BARDA funding [6] Margin Analysis - OPKO Health's gross profit fell by 24.2% year over year to $64.1 million, with a gross margin contraction of 290 basis points to 43.2% [7] - Selling, general and administrative expenses decreased by 24.6% to $50.5 million, while research and development expenses increased by 7.9% to $32.8 million [7] Operating Loss and Financial Position - The operating loss for Q4 2025 was $38.3 million, compared to a loss of $33.1 million in the prior year [8] - At the end of Q4 2025, OPKO Health had cash and cash equivalents of $369.1 million, down from $428.9 million at the end of Q3 2025 [9] Guidance - For Q1 2026, OPKO expects total revenues between $125 million and $140 million, with a full-year revenue outlook of $530 million to $560 million [12] - Product sales are projected to be between $38 million and $45 million for Q1 and $160 million to $170 million for 2026 [13] Strategic Developments - The fourth quarter highlighted OPKO's strategic transformation and financial discipline, particularly following the BioReference asset sale, which streamlined the diagnostics business [14] - The 4Kscore volumes grew year over year, supported by an updated FDA label, while cost rationalization initiatives improved the expense structure [15] - In therapeutics, OPKO advanced multiple clinical-stage programs and collaborations, reinforcing the validation of its multispecific antibody platform [16][17]